UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
UroGen Pharma (URGN) will report third quarter 2026 financial results on November 4, 2026, before the stock market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
UroGen Pharma (URGN) will report third quarter 2026 financial results on November 4, 2026, before the stock market opens.
A conference call and live audio webcast will follow at 10:00 AM Eastern Time. The public webcast will be available on UroGen’s Investor Relations website, with a replay available for approximately 30 days.
Key Figures
- Results reporting date
- November 4, 2026
- Third-quarter 2026 results scheduled before market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET
PRINCETON, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2026 financial results on Wednesday, November 4th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and our second product for adult patients with recurrent LG-IR-NMIBC, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
